Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

78.13 -0.39 (-0.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,878,536
Open 78.48
Bid (Size) 78.15 (1)
Ask (Size) 78.99 (1)
Prev. Close 78.52
Today's Range 78.08 - 79.45
52wk Range 60.47 - 80.86
Shares Outstanding N/A
Dividend Yield 1.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UK Agency Says AstraZeneca's Breast Cancer Drug Enhertu Is Expensive, CEO Pascal Soriot Urges Review Of Drug Pricing Assessment
AstraZeneca CEO Pascal Soriot urges the UK government to reassess drug funding after NICE deems Enhertu too costly, highlighting concerns over new methodology affecting advanced cancer treatments and... 
Via Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
These stocks arguably deserve more respect from investors. 
Via The Motley Fool

Performance

YTD
+14.23%
+14.23%
1 Month
-2.03%
-2.03%
3 Month
+4.13%
+4.13%
6 Month
+16.58%
+16.58%
1 Year
+12.61%
+12.61%

More News

Read More
7 Explosive Growth Stocks Set to Soar in 2024
Via InvestorPlace
Why AstraZeneca Stock Is Sliding Today
Via The Motley Fool
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Economy
AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook
Via Investor's Business Daily
AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines
Via Benzinga
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Via Benzinga
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
AstraZeneca’s H1 and Q2 2024 Financial Results
From AstraZeneca
Via Business Wire
AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
Via InvestorPlace
American Airlines, AstraZeneca And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Via Benzinga
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
Via Benzinga
Biotech Bull Market Is Intact But SMIDs Are Too Volatile
Via Talk Markets
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Via Benzinga
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
Via The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Via Benzinga
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
Via Benzinga
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
Via Benzinga
Exposures COVID-19
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
Via InvestorPlace
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
Via InvestorPlace
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
Via Benzinga
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.